Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 (abstract P70). Overview of adverse events.

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

  

Galcanezumab

Event

Placebo

N=1451

n (%)

120-mg

N=705

n (%)

240-mg

N=730

n (%)

Combined

N=1435

n (%)

Deaths

0

0

0

0

SAE

14 (1.0)

12 (1.7)

11 (1.5)

23 (1.6)

DCAE

24 (1.7)

13 (1.8)

22 (3.0)†

35 (2.4)

TEAE

827 (57.0)

441 (62.6)†

472 (64.7)‡

913 (63.6)‡

  1. Abbreviations: SAE Serious adverse events, DCAE discontinuation due to an adverse event, TEAE Treatment-emergent adverse events
  2. †Indicates P < .05 compared with placebo
  3. ‡Indicates P < .001 compared with placebo
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us